Daily Stock Analysis, DRNA, Dicerna Pharmaceuticals Inc, priceseries

Dicerna Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
26.75
Close
26.79
High
27.68
Low
26.16
Previous Close
26.73
Daily Price Gain
0.06
YTD High
27.68
YTD High Date
Dec 13, 2019
YTD Low
9.39
YTD Low Date
Jan 29, 2019
YTD Price Change
15.02
YTD Gain
127.61%
52 Week High
27.68
52 Week High Date
Dec 13, 2019
52 Week Low
9.31
52 Week Low Date
Dec 24, 2018
52 Week Price Change
14.64
52 Week Gain
120.49%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 10. 2017
2.59
Feb 22. 2017
2.84
7 Trading Days
9.61%
Link
LONG
Jul 20. 2017
3.56
Jul 26. 2017
3.75
4 Trading Days
5.27%
Link
LONG
Sep 7. 2017
3.42
Oct 10. 2017
5.64
23 Trading Days
65.05%
Link
LONG
Oct 31. 2017
5.39
Nov 27. 2017
8.76
18 Trading Days
62.48%
Link
LONG
Dec 20. 2017
7.98
Jan 5. 2018
8.94
10 Trading Days
11.97%
Link
LONG
Feb 14. 2018
9.60
Mar 15. 2018
13.53
20 Trading Days
40.99%
Link
LONG
Apr 26. 2018
11.96
May 11. 2018
13.33
11 Trading Days
11.48%
Link
LONG
Feb 26. 2019
11.28
Mar 6. 2019
12.02
6 Trading Days
6.54%
Link
LONG
Mar 14. 2019
12.31
Apr 9. 2019
14.57
18 Trading Days
18.34%
Link
LONG
Jun 4. 2019
12.39
Jul 2. 2019
15.15
20 Trading Days
22.30%
Link
LONG
Nov 11. 2019
17.93
Dec 9. 2019
24.29
19 Trading Days
35.45%
Link
Company Information
Stock Symbol
DRNA
Exchange
NasdaqGS
Company URL
http://www.dicerna.com
Company Phone
617 621 8097
CEO
Douglas M. Fambrough
Headquarters
Massachusetts
Business Address
87 CAMBRIDGEPARK DRIVE, CAMBRIDGE, MA 02140
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001399529
About

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. It is focused on the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James C. Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.

Description

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company's development programs include DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1) through targeting the gene encoding the liver enzyme glycolate oxidase; and other rare inherited diseases involving genes expressed in the liver. It is also developing DCR-MYC, which is in Phase I clinical study for the treatment of various cancers in patients with solid tumors, multiple myeloma, or lymphoma, as well as in Phase Ib/II clinical trial to treat cancer in patients with advanced hepatocellular carcinoma. In addition, the company is developing KRAS oncogene, a gene that is mutated in various cancers, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer; and a therapeutic targeting a second cancer-related gene. It has a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. for the research, development, and commercialization of Dicer substrate short interfering RNAs (DsiRNA) molecules and drug delivery technologies for therapeutic targets in oncology; license agreement with City of Hope, an academic research and medical center to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans; and license agreement with Plant Bioscience Limited to research, discover, develop, manufacture, sell, import, and export products incorporating short RNA molecules. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.